



---

Noxopharm Limited ([ASX:NOX](#)) | ASX Announcement | 11 August 2021

---

## Additional Details on Collaboration with U.S. National Cancer Institute

---

**Sydney Australia 11 August 2021: Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX)**, at the request of the ASX, provides further information regarding the announcement on 9 August 2021 of the collaboration with the U.S. National Cancer Institute (NCI).

The collaboration is material to Noxopharm as it contributes to the Company's endeavours to bring into the clinic a new class of drug designed to tame aggressive brain cancers. This new class has an intended first-in-class action designed to stop brain cancers killing healthy brain tissue in order to accommodate an expanding cancer. The NCI collaboration is intended to help confirm the drug's mechanisms of anti-cancer actions and its safety in animals.

The collaboration is in the form of a standard Materials Cooperative Research and Development Agreement (MCRADA) and has an initial term of 12 months, effective immediately with drugs being shipped in coming days. Both parties will discuss continuation of the collaboration on completion of the initial term, with any future collaboration resting entirely with Noxopharm.

The brain cancer program has a fully-costed budget covering the drug's entire pre-clinical program, estimated to last 15-18 months when the lead candidate compound is expected to enter human testing. The NCI collaboration combines a Company cash contribution with in-kind support from the NCI. The Company's cash contribution forms part of the pre-clinical budget.

Each party retains full intellectual property (IP) rights to their respective technologies. In particular, Noxopharm retains full ownership to any patents granted over the test compounds, with molecular structures specifically excluded under the terms of the agreement.

Noxopharm CEO, Graham Kelly, said, "MCRADAs are highly valued because of the access they provide to the expertise and resources within the NCI, the peak cancer research group in the world. In this case, it means working with an eminent group of brain cancer researchers with unique laboratory and animal models. Working with the NCI also carries the potential of them helping future clinical development of what we see as a fresh approach to a long-standing and intractable problem."

**-ENDS-**

*Graham Kelly, CEO and Managing Director of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.*

### **About Noxopharm**

Noxopharm Limited (ASX:NOX) is an Australian clinical-stage drug development company focused on the treatment of cancer and cytokine storm (septic shock).

Veyonda® is the Company's first pipe-line drug candidate currently in Phase 2 clinical trialling. Veyonda® has two main drug actions – a moderating effect on the ceramide/sphingosine-1-phosphate balance and inhibition of STING signalling. Activity against the former target contributes to its dual-acting oncotoxic and immunomodulatory functions designed to enhance the effectiveness and safety of standard oncology treatments, i.e., chemotherapies, radiation therapies and immune checkpoint inhibitors. Activity against the latter target provides an anti-inflammatory effect, as well as contributing to an anti-cancer action, but also potentially blocking septic shock.

Noxopharm is running comprehensive drug discovery programs in both oncology and inflammation, and is the major shareholder of US biotechnology company, Nyrada Inc (ASX:NYR), active in the areas of drug development for cardiovascular and neurological diseases.

To learn more, please visit: [noxopharm.com](http://noxopharm.com)

#### **Investor, Corporate & Media enquiries:**

Prue Kelly  
M: 0459 022 445  
E: [info@noxopharm.com](mailto:info@noxopharm.com)

#### **Company Secretary:**

David Franks  
T: +61 2 8072 1400  
E: [David.Franks@automicgroup.com.au](mailto:David.Franks@automicgroup.com.au)

### **Forward Looking Statements**

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.